[European Commission approves first Respiratory Syncytial virus Vaccine] the European Commission issued a communiqu é on the evening of June 6 local time, saying that the commission approved the marketing of the first respiratory syncytial virus vaccine, Arexvy, in the European Union on the same day to protect people aged 60 and above from lower respiratory diseases caused by respiratory syncytial virus. The communique said that respiratory syncytial virus infection increased in EU countries last winter, so people are particularly looking forward to the decision to approve the launch of the Arexvy vaccine in the European Union. In view of the significant public health benefits of preventing respiratory syncytial virus infection in the elderly, the European Commission has accelerated the vaccine approval process in accordance with the accelerated evaluation mechanism of the European Drug Administration.